Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
2000 1
2003 1
2004 1
2005 1
2007 3
2008 5
2010 2
2011 3
2012 2
2013 1
2014 4
2015 2
2016 2
2017 3
2018 3
2019 3
2020 4
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Primary Peritoneal Adenocarcinoma"
Page 1
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Xu RH, et al. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7. Epub 2021 Oct 7. Lancet Gastroenterol Hepatol. 2021. PMID: 34626550 Clinical Trial.
METHODS: RAINBOW-Asia was a randomised, double-blind, placebo-controlled, phase 3 trial done at 32 centres in China, Malaysia, the Philippines, and Thailand. ...Randomisation was stratified by Eastern Cooperative Oncology Group performance status and presence …
METHODS: RAINBOW-Asia was a randomised, double-blind, placebo-controlled, phase 3 trial done at 32 centres in China, Malaysia, …
Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches.
Guro H, Kim JW, Choi Y, Cho JY, Yoon YS, Han HS. Guro H, et al. Surg Oncol. 2017 Jun;26(2):146-152. doi: 10.1016/j.suronc.2017.03.001. Epub 2017 Mar 7. Surg Oncol. 2017. PMID: 28577720 Review.
Intrahepatic cholangiocarcinoma (ICC) is a common primary hepatic tumor. However, its outcomes are usually worse than those of hepatocellular carcinoma owing to its non-specific presentation and detection at an advanced stage. ...To improve patient survival, liver transpla …
Intrahepatic cholangiocarcinoma (ICC) is a common primary hepatic tumor. However, its outcomes are usually worse than those of hepato …
Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis.
Frassini S, Calabretto F, Granieri S, Fugazzola P, Viganò J, Fazzini N, Ansaloni L, Cobianchi L. Frassini S, et al. Eur J Surg Oncol. 2022 Sep;48(9):1911-1921. doi: 10.1016/j.ejso.2022.05.030. Epub 2022 Jun 2. Eur J Surg Oncol. 2022. PMID: 35688711 Review.
CONCLUSIONS: HIPEC could be considered as a promising technique for prophylaxis and treatment of peritoneal metastasis (PM) in case of borderline resectable and locally advanced disease. ...In addition, our data about PIPAC and NIPEC as palliative treatment in unresecta …
CONCLUSIONS: HIPEC could be considered as a promising technique for prophylaxis and treatment of peritoneal metastasis (PM) in case o …
Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X, Ying H, Cheng Y, Zhao L, Zhao S, Bai C, Zhou J. Li X, et al. J BUON. 2019 Nov-Dec;24(6):2539-2545. J BUON. 2019. PMID: 31983130 Free article.
Multivariate analysis revealed that liver metastasis was independently associated with poor PFS, and both unresected primary tumor and males were significantly associated with poor OS. The survival of three metastatic patients was 52-96 months after combination trea …
Multivariate analysis revealed that liver metastasis was independently associated with poor PFS, and both unresected primary t …
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Ghelardi F, Raimondi A, Morano F, Randon G, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, Pietrantonio F. Ghelardi F, et al. Clin Colorectal Cancer. 2023 Dec;22(4):450-456.e1. doi: 10.1016/j.clcc.2023.08.005. Epub 2023 Aug 11. Clin Colorectal Cancer. 2023. PMID: 37657955
PATIENTS AND METHODS: We conducted a prospective study in patients with relapsed or unresectable PMP and confirmed disease progression at baseline. Patients received MMC (7 mg/m(2) every 6 weeks, up to a maximum of 4 cycles) plus metronomic capecitabine (625 mg/sqm/day b.i …
PATIENTS AND METHODS: We conducted a prospective study in patients with relapsed or unresectable PMP and confirmed disease progressio …
Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial.
Bazarbashi S, Elshenawy MA, Badran A, Aljubran A, Alzahrani A, Almanea H, Alsuhaibani A, Alashwah A, Neimatallah M, Abduljabbar A, Ashari L, Alhomoud S, Ghebeh H, Elhassan T, Alsanea N, Mohiuddin M. Bazarbashi S, et al. Cancer Med. 2022 May;11(10):2056-2066. doi: 10.1002/cam4.4590. Epub 2022 Feb 10. Cancer Med. 2022. PMID: 35146939 Free PMC article. Clinical Trial.
Herein, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer. PATIENTS AND METHODS: This was a phase II, single-arm trial. Eligible patients had a diagnosis of rectal adenocarcinoma …
Herein, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal ca …
Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction.
Hiramoto S, Kikuchi A, Tetsuso H, Yoshioka A, Kohigashi Y, Maeda I. Hiramoto S, et al. Int J Clin Oncol. 2018 Dec;23(6):1090-1094. doi: 10.1007/s10147-018-1317-0. Epub 2018 Jul 17. Int J Clin Oncol. 2018. PMID: 30019177
BACKGROUND: Bleeding and obstruction are common localized symptoms in patients with unresectable gastric cancer. Although there are several reports about surgical and endoscopic therapies for gastric cancer, there are few regarding palliative radiation therapy. ...Adverse …
BACKGROUND: Bleeding and obstruction are common localized symptoms in patients with unresectable gastric cancer. Although there are s …
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW, Wang J, Poddubskaya E, Pan H, Rha SY, Zhang R, Hirano H, Spigel D, Yamaguchi K, Chao Y, Wyrwicz L, Disel U, Cid RP, Fornaro L, Evesque L, Wang H, Xu Y, Li J, Sheng T, Yang S, Li L, Moehler M, Xu RH; RATIONALE-305 Investigators. Qiu MZ, et al. BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876. BMJ. 2024. PMID: 38806195 Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. ...TRIAL REGISTRATION: ClinicalT …
OBJECTIVE: To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced g …
Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, Inoue M, Mizumoto T, Kubota T, Yanagida E, Murayama T, Miyanari N, Baba H. Miyata T, et al. Anticancer Res. 2023 Feb;43(2):943-947. doi: 10.21873/anticanres.16239. Anticancer Res. 2023. PMID: 36697062
BACKGROUND/AIM: Conversion surgery (CS) following atezolizumab plus bevacizumab (Atez+Bev) is a treatment strategy for unresectable hepatocellular carcinoma (UR-HCC). Herein, we report a case of CS after transcatheter arterial embolization (TAE) and Atez+Bev for primary …
BACKGROUND/AIM: Conversion surgery (CS) following atezolizumab plus bevacizumab (Atez+Bev) is a treatment strategy for unresectable h …
Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Hompes D, Boot H, van Tinteren H, Verwaal V. Hompes D, et al. J Surg Oncol. 2011 Sep 1;104(3):269-73. doi: 10.1002/jso.21937. Epub 2011 Apr 4. J Surg Oncol. 2011. PMID: 21465492 Clinical Trial.
BACKGROUND AND OBJECTIVES: For unresectable peritoneal carcinomatosis (PC) median overall survival (OS) is 5-6 months. ...Primary tumors were right-sided in >50% and had been previously resected in >58%, 74.4% of PC occurred synchronously. ...
BACKGROUND AND OBJECTIVES: For unresectable peritoneal carcinomatosis (PC) median overall survival (OS) is 5-6 months. ...P …
40 results